Omeros’ OncotoX program for AML consists of proprietary targeted, engineered molecules (about half the size of an antibody) that deliver a toxic payload within the cancer cells, thereby killing ...

Omeros Corporation (Nasdaq: OMER) today announced the establishment of the Omeros Oncology Clinical Steering Committee to ...

Seattle-based biotech company Curi Bio has settled into its new 13,942-square-foot space in Interbay. The company moved to ...

SEATTLE, April 10, 2025--Omeros Corporation (Nasdaq: OMER) today announced the establishment of the Omeros Oncology Clinical Steering Committee to advance Omeros’ OncotoX biologics program ...

Analysts expect the Seattle, Washington-based company to report quarterly loss at 78 cents per share, versus a year-ago loss of 69 cents per share, according to data from Benzinga Pro. On March 21, ...

Omeros (NASDAQ:OMER – Get Free Report) is anticipated to issue its quarterly earnings data before the market opens on Monday, ...

Omeros (NASDAQ:OMER – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at D. Boral Capital in a note issued to investors on Tuesday,Benzinga reports. They presently have ...

We are pleased to announce that our narsoplimab BLA for the treatment of TA-TMA was resubmitted to FDA earlier this month, with the MAA slated ...

SEATTLE (AP) — SEATTLE (AP) — Omeros Corporation (OMER) on Monday reported a loss of $31.4 million in its fourth quarter. The Seattle-based company said it had a loss of 54 cents per share. Losses, ...

Needham analyst Serge Belanger maintained a Hold rating on Omeros (OMER – Research Report) today. The company’s shares opened today at ...